^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CS1002 (ipilimumab biosimilar)

    i
    Other names: CS1002, CS-1002, CS 1002, SHR-8068, SHR8068, SHR 8068
    Company:
    CStone Pharma, Jiangsu Hengrui Pharma
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    5d
    A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2/3, N=165, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    6d
    SHR-8068-301: A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=590, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    18d
    Multicenter, open-access Phase II clinical study of SHR-4849 injection combined with other anti-tumor drugs in patients with malignant solid tumors (ChiCTR2600117863)
    P2, N=120, Shandong Cancer Hospital; Suzhou Shengdiya Biomedical Co., LTD
    New P2 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    cisplatin • carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    1m
    SHR-A1921-205: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=124 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    1m
    Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=134, Not yet recruiting, Fudan University
    New P2 trial
    |
    Erbitux (cetuximab) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • CS1002 (ipilimumab biosimilar) • HRS-4642
    2ms
    A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2/3, N=165, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2/3 trial
    |
    CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    3ms
    A Single-Center Study to Evaluate the Efficacy and Safety of Transarterial Chemoembolization (TACE) Combined with SHR-8068, Atebolizumab, and Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (ChiCTR2600117754)
    P=N/A, N=28, Completed, Lishui Central Hospital; Lishui Central Hospital
    New trial
    |
    Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar)
    3ms
    SHR-8068-303: A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (clinicaltrials.gov)
    P3, N=604, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    4ms
    Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov)
    P1/2, N=139, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • imdatifan (NKT2152)
    5ms
    CATALIS: Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Mismatch repair • MSI-H • dMMR
    |
    capecitabine • oxaliplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    6ms
    Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov)
    P1/2, N=139, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • imdatifan (NKT2152)
    6ms
    Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=460, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)